The Institute for Oriental and Classical Studies (IOCS) at HSE University is developing an electronic database of Chinese mythological characters and motifs. Because nothing like it has ever been compiled, it meets an enormous demand. Project originators Elizaveta Volchkova, Olga Mazo, Aglaya Starostina and Alevtina Solovyova told IQ what they are attempting to accomplish and why Chinese mythology is both complicated and fascinating.

At the twelfth BRICS summit held on November 17, Russian President Vladimir Putin and President of the People's Republic of China Xi Jinping spoke via videoconference about the importance of the BRICS Energy Research Cooperation Platform. Researchers from HSE Institute for Statistical Studies and Economics of Knowledge and the Institute for Economics and Regulation of Natural Monopolies are involved in the work of the Platform.

One of the biggest headlines of recent days has been the announcement made by Pfizer, a U.S.-based company, and BioNTech, Germany, that BNT162b2, a COVID-19 vaccine they are developing, has proved to be 90% effective in its Phase 3 clinical trial. The news was met with big excitement all over the world. However, the Pfizer-BioNTech vaccine is based on a new platform, which is still understudied. According to protocol, its trial will be complete only in 2022. IQ talked to Larisa Popovich, Director of the HSE Institute for Health Economics, about the differences between the U.S.-German and the Russian Sputnik V vaccines, and about the chances of beating COVID-19 with massive immunization in the upcoming months.